O'Shaughnessy Asset Management, LLC Eagle Pharmaceuticals, Inc. Transaction History

O'Shaughnessy Asset Management, LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$41.26 - $51.35 $112,804 - $140,390	-2,734 Reduced 36.25%	4,809 $214,000
Q1 2022 May 13, 2022	SELL	$44.58 - $52.6 $1,694 - $1,998	-38 Reduced 0.5%	7,543 $373,000
Q4 2021 Feb 11, 2022	SELL	$45.82 - $56.9 $9,622 - $11,949	-210 Reduced 2.7%	7,581 $386,000
Q3 2021 Nov 10, 2021	BUY	$43.79 - $55.78 $66,079 - $84,172	1,509 Added 24.02%	7,791 $435,000
Q2 2021 Aug 09, 2021	BUY	$36.86 - $44.5 $201,919 - $243,771	5,478 Added 681.34%	6,282 $269,000
Q1 2021 May 14, 2021	BUY	$40.32 - $50.97 $32,417 - $40,979	804 New	804 $34,000
Q4 2020 Feb 11, 2021	SELL	$41.72 - $51.34 $380,444 - $468,169	-9,119 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$37.02 - $51.28 $407 - $564	-11 Reduced 0.12%	9,119 $388,000
Q2 2020 Aug 13, 2020	BUY	$43.24 - $55.02 $475 - $605	11 Added 0.12%	9,130 $439,000
Q1 2020 May 13, 2020	SELL	$34.37 - $60.07 $6,049 - $10,572	-176 Reduced 1.89%	9,119 $421,000
Q4 2019 Feb 12, 2020	BUY	$54.32 - $64.31 $504,904 - $597,761	9,295 New	9,295 $557,000
Q1 2019 May 10, 2019	SELL	$38.66 - $51.82 $48,866 - $65,500	-1,264 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$36.72 - $67.73 $125,288 - $231,094	-3,412 Reduced 72.97%	1,264 $51,000
Q3 2018 Nov 06, 2018	BUY	$66.65 - $83.86 $12,796 - $16,101	192 Added 4.28%	4,676 $324,000
Q2 2018 Aug 10, 2018	SELL	$51.25 - $76.62 $4,458 - $6,665	-87 Reduced 1.9%	4,484 $339,000
Q1 2018 May 08, 2018	BUY	$52.16 - $66.86 $237,588 - $304,547	4,555 Added 28468.75%	4,571 $241,000
Q4 2017 Feb 13, 2018	BUY	$49.6 - $60.87 $793 - $973	16	16 $1,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of O'Shaughnessy Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on O'Shaughnessy Asset Management, LLC with notifications on news.